echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Kang Zhe Pharmaceuticals "Sedo Sta tablets" declared clinical

    Kang Zhe Pharmaceuticals "Sedo Sta tablets" declared clinical

    • Last Update: 2021-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 17th, Kangzhe Pharmaceuticals' clinical application for a new drug was accepted by CDE.
    is an oral hypoxic induction factor proline hydroxyase inhibitor (HIF-PHI) intended to treat anemia in patients with chronic kidney disease (CKD).
    is developed by Cadila Healthcare, which owns exclusive licensing rights to the product in Chinese mainland, Hong Kong, Macau and Taiwan.
    hypoxic induction factor can not only increase the expression of erythrocyte-producing proteins, but also increase the expression of erythrocyte-producing proteins and promote iron absorption and circulation.
    "How Cells Perceive and Adapt to Oxygen Supply" won the 2019 Nobel Prize in Physiology or Medicine, and the hypooxygenated factor transcription complex is a key finding.
    the world's first approved HIF-PHI-type drug was developed by the company, Rosasta, and was first approved in China.
    , GSK's daprodustat, Otsuka Vadadustat and Torii Pharma's enarodustat were approved in Japan in 2020.
    is currently more of this target drug layout enterprises, related progress can be seen in the following figure: Source: Pharmaceutical Rubik's Cube NextPharma
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.